Metabotropic Glutamate Receptor and Anxiety

Metabotropic Glutamate 수용체와 불안

  • Park, Young-Min (Department of Psychiatry, Ilsanpaik Hospital, Inje University of Korea) ;
  • Yi, Hyeon-Lyung (Department of Psychiatry, Ilsanpaik Hospital, Inje University of Korea) ;
  • Lee, Seung-Hwan (Department of Psychiatry, Ilsanpaik Hospital, Inje University of Korea)
  • 박영민 (인제대학교 의과대학 일산백병원 신경정신과학교실) ;
  • 이현륭 (인제대학교 의과대학 일산백병원 신경정신과학교실) ;
  • 이승환 (인제대학교 의과대학 일산백병원 신경정신과학교실)
  • Received : 2006.06.15
  • Accepted : 2007.01.16
  • Published : 2007.04.30

Abstract

Although treatments of anxiety symptom have been available for decades, the biological basis for anxiety disorders in humans is just beginning to emerge. Recently, there is a growing body of literature suggesting that group II metabotrpic glutamate (mGlu) receptors and group I mGlu receptors are important in the physiological and behavioral sequelae associated with stressful stimuli. Moreover, compounds selective for mGlu receptors, particularly mGlu2/3 and/or mGlu5, have proven as effective as classical anxiolytics in various animal models of anxiety without producing many of the unwanted side effects that are typical of current therapies. This article will focus on the emerging preclinical and clinical data that implicate modulation of the mGlu receptors as a potential anxiolytic strategy.

Keywords